COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
- PMID: 34458098
- PMCID: PMC8383479
- DOI: 10.1016/j.idcr.2021.e01256
COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura
Abstract
We present a 62-year-old gentleman with history of Crohn's disease, G6PD deficiency, who presented with immune-mediated thrombotic thrombocytopenia purpura (iTTP) one week after the diagnosis of COVID-19 infection. He was admitted with worsening dyspnea, acute renal failure, and profound thrombocytopenia with marked schistocytosis on peripheral smear. ADAMTS13 level was severely deficient. He was treated with oral prednisone, plasma exchange and rituximab with complete clinical resolution. Given the temporal association of this recurrent episode of iTTP with COVID-19 infection and no other discernible cause, COVID-19 infection was the most likely trigger.
Keywords: ADAMTS13; COVID-19; thrombotic thrombocytopenic purpura.
© 2021 Published by Elsevier Ltd.
Figures
Similar articles
-
Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature.Front Med (Lausanne). 2022 May 17;9:890661. doi: 10.3389/fmed.2022.890661. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35655852 Free PMC article.
-
Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review.Rheumatol Int. 2023 Mar;43(3):551-557. doi: 10.1007/s00296-022-05260-8. Epub 2022 Dec 28. Rheumatol Int. 2023. PMID: 36576539 Free PMC article. Review.
-
Acquired Thrombotic Thrombocytopenic Purpura Without Anti-ADAMTS13 Antibody Caused by Influenza A (H1N1) Virus Successfully Treated by Plasma Exchange: A Case Report.Am J Case Rep. 2021 Aug 2;22:e932251. doi: 10.12659/AJCR.932251. Am J Case Rep. 2021. PMID: 34334786 Free PMC article.
-
Acute Hepatitis E Induced the First Episode of Immune-Mediated Thrombotic Thrombocytopenic Purpura: The First Case Report.Infect Drug Resist. 2023 Aug 9;16:5149-5154. doi: 10.2147/IDR.S418430. eCollection 2023. Infect Drug Resist. 2023. PMID: 37581168 Free PMC article.
-
[Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].Transfus Clin Biol. 2021 Nov;28(4):380-385. doi: 10.1016/j.tracli.2021.08.347. Epub 2021 Aug 28. Transfus Clin Biol. 2021. PMID: 34464709 Review. French.
Cited by
-
Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024060. doi: 10.4084/MJHID.2024.060. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38984099 Free PMC article. Review.
-
Coronavirus disease 2019-associated thrombotic microangiopathy treated with plasma exchange and antihypertensive therapy in a patient with HIV: A case report with literature review.Medicine (Baltimore). 2023 Oct 13;102(41):e35469. doi: 10.1097/MD.0000000000035469. Medicine (Baltimore). 2023. PMID: 37832064 Free PMC article. Review.
-
TTP-like syndrome and its relationship with complement activation in critically ill patients with COVID-19: A cross-sectional study.Heliyon. 2023 Jun;9(6):e17370. doi: 10.1016/j.heliyon.2023.e17370. Epub 2023 Jun 16. Heliyon. 2023. PMID: 37350773 Free PMC article.
-
Novel Classification of Thrombotic Disorders Based on Molecular Hemostasis and Thrombogenesis Producing Primary and Secondary Phenotypes of Thrombosis.Biomedicines. 2022 Oct 26;10(11):2706. doi: 10.3390/biomedicines10112706. Biomedicines. 2022. PMID: 36359229 Free PMC article. Review.
-
Impact of Concomitant Thrombotic Thrombocytopenic Purpura on COVID-19 Mortality and Morbidity: A Nationwide Inpatient Sample Analysis.Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231219252. doi: 10.1177/10760296231219252. Clin Appl Thromb Hemost. 2023. PMID: 38099718 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous